MicroVision, Inc.
27.4.2022 22:21:08 CEST | ACCESS Newswire | Press release
REDMOND, WA / ACCESSWIRE / April 27, 2022 / MicroVision, Inc. (NASDAQ:MVIS), a leader in MEMS-based solid-state automotive lidar and ADAS solutions, today announced its first quarter 2022 results.
"We made significant progress in the first quarter of 2022. We track tested our integrated Long Range Lidar sensor and perception software, demonstrating promising ground-truth data of our high-fidelity/low-latency solution at speeds of over 60 mph," said Sumit Sharma, MicroVision's Chief Executive Officer. "We continue to receive positive feedback and interest from automotive OEMs and Tier 1 suppliers for our best-in-class product with cost advantages."
"We began our testing in the U.S. and expect to conduct several more rounds of tests of our high-speed Highway Pilot system both in the U.S. and Germany during the second quarter as we work to deliver on our 2022 objectives," continued Sharma.
Key Financial Highlights for Q1 2022
- Revenue for the first quarter of 2022 was $0.4 million, compared to $0.5 million for the first quarter of 2021.
- Net loss for the first quarter of 2022 was $13.2 million, or $0.08 per share, which includes $3.7 million of non-cash, share-based compensation expense, compared to a net loss of $6.2 million, or $0.04 per share, which includes $1.6 million of non-cash, share-based compensation expense, for the first quarter of 2021.
- Adjusted EBITDA for the first quarter of 2022 was negative $9.0 million, compared to negative $4.3 million in the first quarter of 2021.
- Cash used in operations for the first quarter of 2022 was $10.9 million, compared to cash used in operations for the first quarter in 2021 of $4.5 million.
- The Company ended the first quarter of 2022 with $103.3 million in cash and cash equivalents including investment securities, compared to $115.4 million at the end of December 31, 2021.
Conference Call and Webcast: Q1 2022 Results
MicroVision will host a conference call and webcast, consisting of prepared remarks by management, a slide presentation, and a question-and-answer session at 2:00 PM PT/5:00 PM ET on Wednesday, April 27, 2022 to discuss the financial results and provide a business update. Analysts and investors may pose questions for management during the live webcast on April 27, 2022.
The live webcast and slide presentation can be accessed on the Company's Investor Relations website under the Events tab at https://ir.microvision.com/events. The webcast will be archived on the website for future viewing.
About MicroVision
MicroVision is a pioneering company in MEMS based laser beam scanning technology that integrates MEMS, lasers, optics, hardware, algorithms and machine learning software into its proprietary technology to address existing and emerging markets. The Company's integrated approach uses its proprietary technology today to develop automotive lidar sensors and provide solutions for advanced driver-assisted systems (ADAS), leveraging its experience building augmented reality micro-display engines, interactive display modules and consumer lidar modules.
For more information, visit the Company's website at www.microvision.com, on Facebook at www.facebook.com/microvisionincor follow MicroVision on Twitter at @MicroVision.
MicroVision is a trademark of MicroVision, Inc. in the United States and other countries. All other trademarks are the properties of their respective owners.
Non-GAAP information
To supplement MicroVision's condensed financial statements presented in accordance with GAAP, the Company presents investors with the non-GAAP financial measure "adjusted EBITDA." Adjusted EBITDA consists of GAAP net income (loss) excluding the impact of the following: interest income and interest expense; income tax expense; depreciation and amortization; and share-based compensation.
MicroVision believes that the presentation of adjusted EBITDA provides important supplemental information to management and investors regarding financial and business trends, provides consistency and comparability with MicroVision's past financial reports, and facilitates comparisons with other companies in the Company's industry, many of which use similar non-GAAP financial measures to supplement their GAAP results. Internally, management uses this non-GAAP measure when evaluating operating performance because the exclusion of the items described above provides an additional useful measure of the Company's operating results and facilitates comparisons of the Company's core operating performance against prior periods and its business objectives. Externally, the Company believes that adjusted EBITDA is useful to investors in their assessment of MicroVision's operating performance and the valuation of the Company.
Adjusted EBITDA is not calculated in accordance with GAAP, and should be considered supplemental to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. Non-GAAP financial measures have limitations in that they do not reflect all of the costs associated with the operations of MicroVision's business as determined in accordance with GAAP. The Company expects to continue to incur expenses similar to the non-GAAP adjustments described above, and exclusion of these items from its non-GAAP financial measure should not be construed as an inference that these costs are unusual or infrequent. The Company compensates for limitations of the measure by prominently disclosing GAAP net income (loss), which the Company believes is the most directly comparable GAAP measure, and providing investors with a reconciliation from GAAP net income (loss) to adjusted EBITDA.
MicroVision has included a reconciliation of GAAP net income (loss) to adjusted EBITDA for the relevant periods.
Forward-Looking Statements
Certain statements contained in this release, including the Company's plans regarding product demonstration and product capabilities are forward-looking statements that involve a number of risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those projected in such forward-looking statements include the risk its ability to operate with limited cash or to raise additional capital when needed; market acceptance of its technologies and products or for products incorporating its technologies; the failure of its commercial partners to perform as expected under its agreements, including from the impact of COVID-19 (coronavirus); its financial and technical resources relative to those of its competitors; its ability to keep up with rapid technological change; government regulation of its technologies; its ability to enforce its intellectual property rights and protect its proprietary technologies; the ability to obtain customers and develop partnership opportunities; the timing of commercial product launches and delays in product development; the ability to achieve key technical milestones in key products; dependence on third parties to develop, manufacture, sell and market its products; potential product liability claims; its ability to maintain its listing on The Nasdaq Stock Market, and other risk factors identified from time to time in the Company's SEC reports, including the Company's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other reports filed with the SEC. These factors are not intended to represent a complete list of the general or specific factors that may affect the Company. It should be recognized that other factors, including general economic factors and business strategies, may be significant, now or in the future, and the factors set forth in this release may affect the Company to a greater extent than indicated. Except as expressly required by federal securities laws, the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changes in circumstances or any other reason.
MicroVision, Inc.
Balance Sheet
(In thousands)
(Unaudited)
| March 31, | December 31, | |||||||
| 2022 | 2021 | |||||||
Assets | ||||||||
Current Assets | ||||||||
Cash and cash equivalents | $ | 55,611 | $ | 82,647 | ||||
Investment securities, available-for-sale | 47,651 | 32,720 | ||||||
Inventory | 1,815 | 1,780 | ||||||
Other current assets | 1,865 | 2,283 | ||||||
Total current assets | 106,942 | 119,430 | ||||||
Property and equipment, net | 3,248 | 3,026 | ||||||
Operating lease right-of-use asset | 5,368 | 5,577 | ||||||
Restricted cash | 1,092 | 1,092 | ||||||
Intangible assets, net | 105 | 115 | ||||||
Other assets | 1,014 | 985 | ||||||
Total assets | $ | 117,769 | $ | 130,225 | ||||
Liabilities and Shareholders' Equity | ||||||||
Current Liabilities | ||||||||
Accounts payable | $ | 1,919 | $ | 3,584 | ||||
Accrued liabilities | 1,288 | 1,170 | ||||||
Contract liabilities | 4,915 | 5,265 | ||||||
Other current liabilities | 474 | 1,181 | ||||||
Current portion of long-term debt | 98 | 392 | ||||||
Current portion of operating lease liability | 686 | 849 | ||||||
Current portion of finance lease obligations | 24 | 21 | ||||||
Total current liabilities | 9,404 | 12,462 | ||||||
Operating lease liability, net of current portion | 4,882 | 4,983 | ||||||
Finance lease obligations, net of current portion | 15 | 26 | ||||||
Total liabilities | 14,301 | 17,471 | ||||||
Commitments and contingencies | ||||||||
Shareholders' Equity | ||||||||
Common stock at par value | 165 | 164 | ||||||
Additional paid-in capital | 746,028 | 742,042 | ||||||
Accumulated other comprehensive loss | (124 | ) | (19 | ) | ||||
Accumulated deficit | (642,601 | ) | (629,433 | ) | ||||
Total shareholders' equity | 103,468 | 112,754 | ||||||
Total liabilities and shareholders' equity | $ | 117,769 | $ | 130,225 | ||||
MicroVision, Inc.
Statement of Operations
(In thousands, except earnings per share data)
(Unaudited)
| Three months ended March 31, | ||||||||
| 2022 | 2021 | |||||||
Product revenue | $ | - | $ | - | ||||
License and royalty revenue | 350 | 479 | ||||||
Total revenue | 350 | 479 | ||||||
Cost of product revenue | 4 | (5 | ) | |||||
Total cost of revenue | 4 | (5 | ) | |||||
Gross margin | 346 | 484 | ||||||
Research and development expense | 7,593 | 4,462 | ||||||
Sales, marketing, general and administrative expense | 5,877 | 2,247 | ||||||
Total operating expenses | 13,470 | 6,709 | ||||||
Loss from operations | (13,124 | ) | (6,225 | ) | ||||
Other expense, net | (44 | ) | (6 | ) | ||||
Net loss | $ | (13,168 | ) | $ | (6,231 | ) | ||
Net loss per share - basic and diluted | $ | (0.08 | ) | $ | (0.04 | ) | ||
Weighted-average shares outstanding - basic and diluted | 164,563 | 155,454 | ||||||
MicroVision, Inc.
Reconciliation of GAAP Net Loss to Non-GAAP Measure
(In thousands, except earnings per share data)
(Unaudited)
| Three months ended March 31, | ||||||||
| 2022 | 2021 | |||||||
GAAP net loss | $ | (13,168 | ) | $ | (6,231 | ) | ||
Add Interest (net) | (31 | ) | 5 | |||||
Add Income taxes | - | - | ||||||
Add Depreciation & amorization | 483 | 299 | ||||||
Add Share-based compensation expense | 3,734 | 1,638 | ||||||
Adjusted EBITDA | $ | (8,982 | ) | $ | (4,289 | ) | ||
Investor Relations Contact
Jeff Christensen and Matt Kreps
Darrow Associates Investor Relations
MVIS@darrowir.com
SOURCE: MicroVision, Inc.
View source version on accesswire.com:
https://www.accesswire.com/699143/MicroVision-Announces-First-Quarter-2022-Results
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
SK Tes Ireland Achieves ISO Certification Milestone and Recognized in National Digital Infrastructure Report4.6.2026 15:00:00 CEST | Press release
DUBLIN, IE / ACCESS Newswire / June 4, 2026 / SK tes, a global leader in sustainable technology lifecycle services, today announced that its Ireland facility has successfully passed audits for ISO 9001 (Quality Management), ISO 14001 (Environmental Management), ISO 45001 (Occupational Health & Safety), and ISO 27001 (Information Security Management), reinforcing its commitment to delivering consistent, high-quality, safe and sustainable services worldwide. These certifications are standard across SK tes' global network of facilities and form a core part of the company's operating model. As the newest site within this network, Ireland's certification reflects the structured commissioning process that ensures every SK tes location meets the same rigorous international standards - enabling clients to receive a consistent, secure, and compliant service experience, regardless of geography. In parallel, the Irish business has been recognized in the DII Economic Report 2026, published by Digi
Preservica takes AI for Digital Preservation to the next level with powerful new AI Editions4.6.2026 15:00:00 CEST | Press release
OXFORD, UK AND BOSTON, MA / ACCESS Newswire / June 4, 2026 / Preservica, a global leader in AI-powered Active Digital Preservation™, today announced the launch of its new AI Editions that combine human-centric AI tools with the built-in AI capacity to enable archival and records teams to quickly and safely transform their archives at scale. Developed in collaboration with the Preservica user community, the new AI Editions enable teams to process backlogs up to four times faster, meet privacy, accessibility, and FOI requirements, standardize metadata quality, accelerate content enrichment and discovery, and free time for higher-value work. With ample AI capacity included, teams can save significant time - cutting repetitive, manual work and quickly adding new value to their archives every month: Transcribe hundreds of hours of AV content or OCR thousands of scanned images or Identify PII in hundreds of thousands of documents or Standardize metadata across thousands of assets And more "S
Gedeon Richter Highlights Expanding Biosimilars Portfolio and Scientific Engagement at EULAR 20264.6.2026 14:45:00 CEST | Press release
LONDON, UK / ACCESS Newswire / June 4, 2026 / The Biotechnology Business Unit of Gedeon Richter Plc. (Richter) is present at this year's European Alliance of Associations for Rheumatology's (EULAR) European Congress of Rheumatology, underlining its role as a growing contributor to biologic therapies in Europe. The company also hosted a satellite symposium on the opening day, as part of its engagement with the rheumatology community. Richter's presence at EULAR reflects nearly two decades of focused investment following its strategic entry into biotechnology. Today, it operates a fully integrated biosimilars business with a European development and manufacturing network, including facilities in Budapest and Debrecen in Hungary, operations in Germany, and global partnerships supported by over 1,000 biotech professionals. As part of its scientific program, yesterday Richter hosted the symposium "Prevention, better than treatment - insights on inflammatory joint disease and osteoporosis" c
Media Invitation: Fields Medals and Cutting-Edge Math at ICM 2026 in Philadelphia2.6.2026 20:30:00 CEST | Press release
PHILADELPHIA, PA / ACCESS Newswire / June 2, 2026 / Members of the press are invited to the world's most prestigious mathematics conference, which will take place at the Pennsylvania Convention Center in Philadelphia from July 23 to July 30, 2026. Held every four years, the International Congress of Mathematicians (ICM) includes the announcement of the field's top prizes - including the Fields Medals - as well as top talks from leading mathematicians on cutting-edge developments in the field. Staff reporters and freelance journalists can register to attend the conference free of charge through June 22. Media registration includes access to a press conference with the Fields Medalists and other honorees following their announcement during the July 23 opening ceremony. A press room will also be available during the conference. Discounted hotel room rates are available to attendees. For more information, visit the ICM 2026 website or email icmpressinquiries@simonsfoundation.org. The confe
IXOPAY Launches Payments Intelligence and IXONav, an AI Payments Assistant Built to Unlock Real-Time Insights Across the Payments Journey2.6.2026 06:00:00 CEST | Press release
Company's intelligence layer combines AI-driven analytics with anomaly detection to improve merchant payments optimization, performance and revenue outcomes LEHI, UT / ACCESS Newswire / June 2, 2026 / IXOPAY, the performance layer powering global payments for the agentic era, today announced IXOPAY Payments Intelligence, a unified control center that transforms fragmented payment data into real-time, actionable insights. The company also launched IXONav, a new AI agentic navigator built to unlock key insights at every step in the payments journey. By combining AI-driven analytics, anomaly detection and LLM agents, the platform helps merchants uncover optimization opportunities, improve routing performance, increase authorization rates and reduce per-transaction costs. IXOPAY's no-code payments platform unifies payment orchestration, tokenization, and intelligence, and provides merchants with a configurable infrastructure to optimize their payments performance. The IXOPAY Payments Intel
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
